Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

More patients treated with Vtama achieved vIGA-AD success compared with those who received vehicle cream in both ADORING 1 (45% vs 14%) and ADORING 2 (46% vs 18%). The Food and Drug Administration ...

Please provide your email address to receive an email when new articles are posted on . Dermavant Sciences partner, Japan Tobacco, received approval for Vtama cream 1% in Japan. Approved indications ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. More than a quarter of patients achieved a clear or ...

In patients with moderate atopic dermatitis, the use of Opzelura (ruxolitinib) led to early and sustained improvements in ...

ZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeks Caregivers reported rapid improvement in itch in as ...

A total of 654 adults and children, age six and older, have been enrolled in the INTEGUMENT-1 trial Enrollment continues in INTEGUMENT-2 with topline data from both trials expected by end of 2022 ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful ...

WESTLAKE VILLAGE, Calif. and LAS VEGAS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (ARQT) (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing ...

- The majority of patients, 51.9% (378/728), entered with or achieved complete disease clearance (vIGA-AD™=0) in the 48-week ADORING 3 open-label LTE study. - Most patients, 81.6% (594/728), entered ...